Adipose-derived stem cells (ADSCs) are stem cells extracted from adipocytes. ADSCs have potency similar to bone marrow mesenchymal stem cells. So, ADSCs substitute for bone marrow as a source of stem cells. Several manuals and automatic stem cell separation procedures isolate adipose stem cells (ASCs) from adipose tissue. Flow cytometry can be utilized to isolate ADSCs from other stem cells within a cell solution. Presently, adipose-derived stem cells (ADSCs) are generally used in the production of regenerative medicine due to their anti-inflammatory, anti-apoptotic, pro-angiogenic, anti-scarring properties, and immunomodulatory properties.
MARKET SCOPE
The "Global Adipose Tissue-Derived Stem Cell Therapy Market Analysis to 2028" is a specialized and in-depth study of the biotechnology industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Adipose Tissue-derived stem cell therapy market with detailed market segmentation by cell type, product, disease indication, end use, and geography. The report provides key statistics on the market status of the leading Adipose Tissue-derived stem cell therapy market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on cell type, the global Adipose Tissue-derived stem cell therapy market is segmented into autologous stem cells, allogeneic stem cells.
- On the basis of product, the market is segmented into cell line, culture media. Culture media is again segmented into media, sera, reagent.
- On the basis of disease indication, the market is segmented into cancer, obesity, wounds and injuries, musculoskeletal diseases, cardiovascular diseases, others.
- On the basis of end use, the market is segmented into hospitals and trauma centers, cell banks and tissue banks, research laboratories and academic institutes, others.
MARKET DYNAMICS
Drivers
- Growing awareness about the role of regenerative medicine in disease treatment.
- Rise in the private and public funding to support stem cell based researches.
- Rise in rise in regulatory approvals for adipose derived stem cell.
Restraints
- The high cost associated with stem cell processing, and and ethical issues related to the use of allogeneic stem cell lines are the major restraining factor for this market.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Adipose Tissue-derived stem cell therapy market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Adipose Tissue-derived stem cell therapy market in these regions.
IMPACT OF COVID-19 ON ADIPOSE TISSUE-DERIVED STEM CELL THERAPY MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the Adipose Tissue-derived stem cell therapy market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Adipose Tissue-derived stem cell therapy market are anticipated to lucrative growth opportunities in the future with the rising demand for Adipose Tissue-derived stem cell therapy in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Adipose Tissue-derived stem cell therapy market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- AlloCure, Inc.
- Antria, Inc.
- Celgene Corporation
- Cellleris SA
- Pluristem Therapeutics, Inc.
- Tissue Genesis, Inc.
- Cytori Therapeutics, LLC
- Intrexon, Inc.
- Mesoblast Ltd
- Medipost
The Insight Partner's dediAdipose Tissue-derived stem cell therapyed research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.